Cited by 2,961Protein Degradation and InhibitorsChromatin Remodeling and CancerGenomics and Chromatin Dynamics

The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

Open access

Lovén, Jakob, Hoke, Heather A., Lin, Charles Y., Lau, Ashley, Orlando, David A., Vakoc, Christopher R., Bradner, James E., Lee, Tong Ihn, Young, Richard A.·2013·Cell

DOI 10.1016/j.cell.2013.03.036PMC PMC3760967

Open this paper in CoChat — free account Open PDF

Abstract

Chromatin regulators have become attractive targets for cancer therapy, but it is unclear why inhibition of these ubiquitous regulators should have gene-specific effects in tumor cells. Here, we investigate how inhibition of the widely expressed transcriptional coactivator BRD4 leads to selective inhibition of the MYC oncogene in multiple myeloma (MM). BRD4 and Mediator were found to co-occupy thousands of enhancers associated with active genes. They also co-occupied a small set of exceptionally large super-enhancers associated with genes that feature prominently in MM biology, including the MYC oncogene. Treatment of MM tumor cells with the BET-bromodomain inhibitor JQ1 led to preferential loss of BRD4 at super-enhancers and consequent transcription elongation defects that preferentially impacted genes with super-enhancers, including MYC. Super-enhancers were found at key oncogenic drivers in many other tumor cells. These observations have implications for the discovery of cancer therapeutics directed at components of super-enhancers in diverse tumor types.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2013.03.036

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Topological domains in mammalian genomes identified by analysis of chromatin interactions
Dixon, J. R., Selvaraj, S., Yue, F., Kim, A., Li, Y., Shen, Y., Hu, M., Liu, J. S., & Ren, B. (2012) · Nature · doi:10.1038/nature11082 · Cited by 6,829
NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins
Pruitt, K. D., Tatusova, T. A., & Maglott, D. R. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl842 · Cited by 4,441
Histone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
Self-citation
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Self-citation
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Self-citation
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Epigenetics in Cancer
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,767
Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclassesPreprint
Cabili, M. N., Trapnell, C., Goff, L. A., Koziol, M. J., Tazón‐Vega, B., Regev, A., & Rinn, J. L. (2011) · Genes & Development · doi:10.1101/gad.17446611 · Cited by 3,551

Show all 86 references

Sorted by citations

Items 501–600 of 1,008

JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma
Wong, M., Sun, Y., Xi, Z., Milazzo, G., Poulos, R. C., Bartenhagen, C., Bell, J. L., Mayoh, C., Ho, N., Tee, A. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11132-w · Cited by 99
Non-coding RNAs: The key detectors and regulators in cardiovascular disease
Zhu, L., Ni, L., Sun, L., Zheng, D., & Shao, G. (2020) · Genomics · doi:10.1016/j.ygeno.2020.10.024 · Cited by 101
The long journey to bring a Myc inhibitor to the clinic
Whitfield, J. R., & Soucek, L. (2021) · The Journal of Cell Biology · doi:10.1083/jcb.202103090 · Cited by 101
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1
Zhang, Z., Ma, P., Jing, Y., Yan, Y., Cai, M., Zhang, M., Zhang, S., Peng, H., Ji, Z., Di, W. J., et al. (2015) · Theranostics · doi:10.7150/thno.13178 · Cited by 103
Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors
Tolani, B., Ramakrishnan, G., Punj, V., Matta, H., & Chaudhary, P. M. (2013) · Oncogene · doi:10.1038/onc.2013.242 · Cited by 103
Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases
Clarke, P. A., Ortiz-Ruiz, M.-J., Poele, R. T., Adeniji-Popoola, O., Box, G., Court, W., Czasch, S., Bawab, S. E., Esdar, C., Ewan, K., et al. (2016) · eLife · doi:10.7554/elife.20722 · Cited by 99
RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1
Mill, C. P., Fiskus, W. C., Dinardo, C. D., Qian, Y., Raina, K., Rajapakshe, K., Perera, D. N., Coarfa, C., Kadia, T. M., Khoury, J. D., et al. (2019) · Blood · doi:10.1182/blood.2018893982 · Cited by 98
CDK9 keeps RNA polymerase II on track
Egloff, S. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03878-8 · Cited by 104
MYC‐associated and double‐hit lymphomas: A review of pathobiology, prognosis, and therapeutic approaches
Petrich, A. M., Nabhan, C., & Smith, S. M. (2014) · Cancer · doi:10.1002/cncr.28899 · Cited by 98
Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response
Agirre, X., Meydan, C., Jiang, Y., Gárate, L., Doane, A. S., Li, Z., Verma, A., Paiva, B., Martín-Subero, J. I., Elemento, O., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08679-z · Cited by 99
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
Ge, J. Y., Shu, S., Kwon, M., Jovanović, B., Murphy, K. C., Gulvady, A. C., Fassl, A., Trinh, A. C., Kuang, Y., Heavey, G. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16170-3 · Cited by 102
Integrative pan cancer analysis reveals epigenomic variation in cancer type and cell specific chromatin domains
Gopi, L. K., & Kidder, B. L. (2021) · Nature Communications · doi:10.1038/s41467-021-21707-1 · Cited by 101
Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
Li, B., Chonghaile, T. N., Fan, Y., Madden, S. F., Klinger, R. W., O’Connor, A. E., Walsh, L., O’Hurley, G., Udupi, G. M., Joseph, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2546 · Cited by 97
HPV integration hijacks and multimerizes a cellular enhancer to generate a viral-cellular super-enhancer that drives high viral oncogene expression
Warburton, A., Redmond, C. J., Dooley, K. E., Fu, H., Gillison, M. L., Akagi, K., Symer, D. E., Aladjem, M. I., & McBride, A. A. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007179 · Cited by 101
DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network
Hamdan, F. H., & Johnsen, S. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812915116 · Cited by 93
Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases
Morgado‐Pascual, J. L., Rayego‐Mateos, S., Tejedor-Santamaria, L., Suárez-Álvarez, B., & Ruiz‐Ortega, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01315 · Cited by 103
Enhancer and super-enhancer dynamics in repair after ischemic acute kidney injury
Wilflingseder, J., Willi, M., Lee, H., Olauson, H., Jankowski, J., Ichimura, T., Erben, R. G., Valerius, M. T., Hennighausen, L. G., & Bonventre, J. V. (2020) · Nature Communications · doi:10.1038/s41467-020-17205-5 · Cited by 96
Enhancer remodeling promotes tumor-initiating activity in NRF2-activated non-small cell lung cancers
Okazaki, K., Anzawa, H., Liu, Z., Ota, N., Kitamura, H., Onodera, Y., Alam, M. M., Matsumaru, D., Suzuki, T., Katsuoka, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19593-0 · Cited by 92
Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancer
Loo, S. Y., Toh, L. P., Xie, W. H., Pathak, E., Tan, W. W. S., Ma, S., Lee, M. Y., Shatishwaran, S., Yeo, J. Z. Z., Yuan, J. X., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh2443 · Cited by 94
An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers
Mahé, M., Dufour, F., Neyret‐Kahn, H., Moreno-Vega, A. I., Béraud, C., Shi, M., Hamaidi, I., Sánchez‐Quiles, V., Krucker, C., Dorland‐Galliot, M., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708163 · Cited by 100
Unravelling the genomic targets of small molecules using high-throughput sequencing
Rodriguez, R., & Miller, K. M. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3796 · Cited by 100
Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma
Jin, Y., Chen, K., Paepe, A. D., Hellqvist, E., Krstic, A. D., Metang, L. A., Gustafsson, C., Davis, R. E., Levy, Y. M., Surapaneni, R., et al. (2018) · Blood · doi:10.1182/blood-2017-09-808063 · Cited by 96
Targeting MYCN in Pediatric and Adult Cancers
Liu, Z., Chen, S. S., Clarke, S., Veschi, V., & Thiele, C. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.623679 · Cited by 96
Pharmacological Inhibition of Core Regulatory Circuitry Liquid–liquid Phase Separation Suppresses Metastasis and Chemoresistance in Osteosarcoma
Lu, B., Zou, C., Yang, M., He, Y., He, J., Zhang, C., Chen, S., Yu, J., Liu, K. Y., Cao, Q., et al. (2021) · Advanced Science · doi:10.1002/advs.202101895 · Cited by 95
RANKL-responsive epigenetic mechanism reprograms macrophages into bone-resorbing osteoclasts
Bae, S., Kim, K., Kang, K., Kim, H., Lee, M. J., Oh, B., Kaneko, K., Ma, S., Choi, J., Kwak, H., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00959-x · Cited by 104
Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations
Ross, J. S., Ali, S. M., Wang, K., Khaira, D., Palma, N. A., Chmielecki, J., Palmer, G. A., Morosini, D., Elvin, J. A., Fernandez, S. V., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3592-z · Cited by 96
A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinoma
Syafruddin, S. E., Rodrigues, P., Vojtasova, E., Patel, S. A., Zaini, M. N., Burge, J., Warren, A. Y., Stewart, G. D., Eisen, T. G., Bihary, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09116-x · Cited by 97
Histone H3K27 acetylation precedes active transcription during zebrafish zygotic genome activation as revealed by live-cell analysis
Sato, Y., Hilbert, L., Oda, H., Wan, Y., Heddleston, J. M., Chew, T., Zaburdaev, V., Keller, P., Lionnet, T., Vastenhouw, N. L., et al. (2019) · Development · doi:10.1242/dev.179127 · Cited by 95
Regulation of programmed cell death by Brd4
Hu, J., Pan, D., Guo, L., Chen, K., & Hu, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05505-1 · Cited by 100
BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
To, K. K. W., Xing, E., Larue, R. C., & Li, P. (2023) · Molecules · doi:10.3390/molecules28073043 · Cited by 103
Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression
Lenhart, R., Kirov, S. A., Desilva, H., Cao, J., Lei, M., Johnston, K., Peterson, R., Schweizer, L., Purandare, A. V., Ross‐Macdonald, P., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0037 · Cited by 95
Progress and challenges in bioinformatics approaches for enhancer identification
Kleftogiannis, D., Kalnis, P., & Bajić, V. B. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbv101 · Cited by 92
Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers
Sanchez, G. J., Richmond, P. A., Bunker, E. N., Karman, S. S., Azofeifa, J. G., Garnett, A. T., Xu, Q., Wheeler, G. E., Toomey, C. M., Zhang, Q., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1225 · Cited by 92
USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia
Jin, Q., Martinez, C. A., Arcipowski, K. M., Zhu, Y., Gutierrez-Diaz, B. T., Wang, K. K., Johnson, M. R., Volk, A. G., Wang, F., Wu, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1740 · Cited by 98
CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia
Pulikkan, J. A., Hegde, M. B., Ahmad, H. M., Belaghzal, H., Illendula, A., Yu, J., O’Hagan, K., Ou, J., Müller‐Tidow, C., Wolfe, S. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.048 · Cited by 92
Emerging concepts of epigenetic dysregulation in hematological malignancies
Ntziachristos, P., Abdel-Wahab, O. I., & Aifantis, I. (2016) · Nature Immunology · doi:10.1038/ni.3517 · Cited by 99
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay
Abruzzese, M. P., Bilotta, M. T., Fionda, C., Zingoni, A., Soriani, A., Vulpis, E., Borrelli, C., Zitti, B., Petrucci, M. T., Ricciardi, M. R., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0362-2 · Cited by 97
Small genomic insertions form enhancers that misregulate oncogenes
Abraham, B. J., Hnisz, D., Weintraub, A. S., Kwiatkowski, N. P., Li, C. H., Li, Z., Weichert‐Leahey, N., Rahman, S., Liu, Y., Etchin, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14385 · Cited by 96
Self-citation
miRNA-32 Drives Brown Fat Thermogenesis and Trans-activates Subcutaneous White Fat Browning in Mice
Ng, R., Hussain, N. A., Zhang, Q., Chang, C. T., Li, H., Fu, Y., Cao, L., Han, W., Stünkel, W., & Xu, F. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.035 · Cited by 93
Advances in targeted degradation of endogenous proteins
Röth, S., Fulcher, L. J., & Sapkota, G. P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03112-6 · Cited by 92
A chemical probe toolbox for dissecting the cancer epigenome
Shortt, J., Ott, C. J., Johnstone, R. W., & Bradner, J. E. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.148 · Cited by 94
Self-citation
Master transcription factors form interconnected circuitry and orchestrate transcriptional networks in oesophageal adenocarcinoma
Chen, L., Huang, M., Plummer, J., Pan, J., Jiang, Y. Y., Yang, Q., Silva, T. C., Gull, N., Chen, S., Ding, L., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318325 · Cited by 93
BET Bromodomain Inhibitors Block Growth of Pancreatic Cancer Cells in Three-Dimensional Collagen
Sahai, V., Kumar, K., Knab, L. M., Chow, C. R., Raza, S. S., Bentrem, D. J., Ebine, K., & Munshi, H. G. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0925 · Cited by 98
INO80 governs superenhancer-mediated oncogenic transcription and tumor growth in melanomaPreprint
Zhou, B., Wang, L., Zhang, S., Bennett, B. D., He, F., Zhang, Y., Xiong, C., Han, L., Diao, L., Li, P., et al. (2016) · Genes & Development · doi:10.1101/gad.277178.115 · Cited by 92
Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer
Dreijerink, K. M. A., Groner, A. C., Vos, E. S. M., Font‐Tello, A., Gu, L., Chi, D., Reyes, J. M., Cook, J., Lim, E., Lin, C. Y., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.025 · Cited by 96
Self-citation
Chromosome territories and the global regulation of the genome
Fritz, A. J., Sehgal, N., Pliss, A., Xu, J., & Berezney, R. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22732 · Cited by 100
Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations
Zhou, S., Treloar, A. E., & Lupien, M. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0745 · Cited by 89
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling
Iniguez, A. B., Alexe, G., Wang, E. J., Roti, G., Patel, S., Chen, L., Kitara, S., Conway, A. S., Robichaud, A. L., Stolte, B., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.005 · Cited by 92
BET proteins: Biological functions and therapeutic interventions
Guo, J., Zheng, Q., & Peng, Y. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108354 · Cited by 96
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
Saenz, D. T., Fiskus, W. C., Manshouri, T., Rajapakshe, K., Krieger, S., Sun, B., Mill, C. P., Dinardo, C. D., Pemmaraju, N., Kadia, T. M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.260 · Cited by 91
ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia
Thirant, C., Ignacimouttou, C., Lopez, C. K., Diop, M. K., Mouël, L. L., Thiollier, C., Siret, A., Dessen, P., Aid, Z., Rivière, J., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.006 · Cited by 93
Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells
Tögel, L., Nightingale, R., Chüeh, A. C., Jayachandran, A., Tran, H., Phesse, T. J., Wu, R., Sieber, O. M., Arango, D., Dhillon, A. S., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0724 · Cited by 90
MYC Modulation around the CDK2/p27/SKP2 Axis
Hydbring, P., Castell, A., & Larsson, L. (2017) · Genes · doi:10.3390/genes8070174 · Cited by 95
Molecular Crosstalk Between MYC and HIF in Cancer
Li, Y., Sun, X., Qian, D. Z., & Dai, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.590576 · Cited by 96
ZFTA–RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma
Arabzade, A., Zhao, Y., Varadharajan, S., Chen, H., Jessa, S., Rivas, B. L., Stuckert, A. J., Solis, M., Kardian, A., Tlais, D., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1066 · Cited by 92
Self-citation
BET bromodomain proteins regulate enhancer function during adipogenesis
Brown, J. D., Feldman, Z. B., Doherty, S. P., Reyes, J. M., Rahl, P. B., Lin, C. Y., Sheng, Q., Duan, Q., Alexander Joel Federation, Kung, A. L., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711155115 · Cited by 90
Self-citation
Mediator complex interaction partners organize the transcriptional network that defines neural stem cells
Quevedo, M., Meert, L., Dekker, M. R., Dekkers, D. H. W., Brandsma, J. H., van den Berg, D. L. C., Özgür, Z., van IJcken, W. F. J., Demmers, J., Fornerod, M. W. J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10502-8 · Cited by 95
NSD2 overexpression drives clustered chromatin and transcriptional changes in a subset of insulated domains
Lhoumaud, P., Badri, S., Rodriguez-Hernaez, J., Sakellaropoulos, T., Sethia, G., Kloetgen, A., Cornwell, M., Bhattacharyya, S., Ay, F., Bonneau, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12811-4 · Cited by 92
Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms
Jia, Q., Chen, S., Tan, Y., Li, Y., & Tang, F. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0428-7 · Cited by 94
Self-Reporting Transposons Enable Simultaneous Readout of Gene Expression and Transcription Factor Binding in Single Cells
Moudgil, A., Wilkinson, M., Chen, X., He, J., Cammack, A. J., Vasek, M. J., Lagunas, T., Qi, Z., Lalli, M. A., Guo, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.037 · Cited by 80
From start to end: Phase separation and transcriptional regulation
Liu, P., Li, E., & Xu, L. (2020) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2020.194641 · Cited by 86
Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia
Wong, R. W. J., Ngoc, P. C. T., Leong, W. Z., Yam, A. W. Y., Zhang, T., Asamitsu, K., Iida, S., Okamoto, T., Ueda, R., Gray, N. S., et al. (2017) · Blood · doi:10.1182/blood-2017-06-792184 · Cited by 90
Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer
Chalakur-Ramireddy, N. K. R., & Pakala, S. B. (2018) · Bioscience Reports · doi:10.1042/bsr20171357 · Cited by 89
ERG promotes the maintenance of hematopoietic stem cells by restricting their differentiationPreprint
Knudsen, K. J., Rehn, M., Hasemann, M. S., Rapin, N., Bagger, F. O., Ohlsson, E., Willer, A., Frank, A.-K., Søndergaard, E., Jendholm, J., et al. (2015) · Genes & Development · doi:10.1101/gad.268409.115 · Cited by 92
Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes
Hill, J. M., Quenelle, D. C., Cardin, R. D., Vogel, J. L., Clément, C., Bravo, F., Foster, T. P., Bosch‐Marcé, M., Raja, P., Lee, J. S., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010643 · Cited by 87
The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma
Bid, H. K., Phelps, D. A., Xaio, L., Guttridge, D. C., Lin, J., London, C. A., Baker, L. H., Mo, X. M., & Houghton, P. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0567 · Cited by 92
Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation
Somerville, T. D. D., Biffi, G., Daßler‐Plenker, J., Hur, S. K., He, X., Vance, K. E., Miyabayashi, K., Xu, Y., Maia-Silva, D., Klingbeil, O., et al. (2020) · eLife · doi:10.7554/elife.53381 · Cited by 87
Self-citation
Illuminating the noncoding genome in cancer
Zhang, X., & Meyerson, M. M. (2020) · Nature Cancer · doi:10.1038/s43018-020-00114-3 · Cited by 86
Trials and tribulations of pancreatic cancer immunotherapy
Principe, D. R., Korc, M., Kamath, S. D., Munshi, H. G., & Rana, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.01.031 · Cited by 95
Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation
Orth, M. F., Surdez, D., Faehling, T., Ehlers, A. C., Marchetto, A., Grossetête, S., Volckmann, R., Zwijnenburg, D. A., Gerke, J. S., Zaïdi, S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111761 · Cited by 90
Identification of human silencers by correlating cross-tissue epigenetic profiles and gene expressionPreprint
Huang, D., Petrykowska, H. M., Miller, B., Elnitski, L. L., & Ovcharenko, I. (2019) · Genome Research · doi:10.1101/gr.247007.118 · Cited by 91
Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins
Raux, B., Voitovich, Y. V., Derviaux, C., Lugari, A., Rebuffet, E., Milhas, S., Priet, S., Roux, T., Trinquet, E., Guillemot, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01708 · Cited by 88
Small-Molecule Targeting of BET Proteins in Cancer
French, C. A. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.04.001 · Cited by 89
Mutational patterns and regulatory networks in epigenetic subgroups of meningioma
Paramasivam, N., Hübschmann, D., Toprak, U. H., Ishaque, N., Neidert, M. C., Schrimpf, D., Stichel, D., Reuß, D., Sievers, P., Reinhardt, A., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02008-w · Cited by 83
BET bromodomain inhibitors
Schwalm, M. P., & Knapp, S. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102148 · Cited by 89
Systematic identification and annotation of human methylation marks based on bisulfite sequencing methylomes reveals distinct roles of cell type-specific hypomethylation in the regulation of cell identity genes
Liu, H., Liu, X., Zhang, S., Lv, J., Li, S., Shang, S., Jia, S., Wei, Y., Wang, F., Su, J., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1332 · Cited by 85
Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival
Katerndahl, C. D. S., Heltemes-Harris, L. M., Willette, M., Henzler, C. M., Frietze, S. E., Yang, R., Schjerven, H., Silverstein, K. A. T., Ramsey, L. B., Hubbard, G. K., et al. (2017) · Nature Immunology · doi:10.1038/ni.3716 · Cited by 83
Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets
Baldauf, M. C., Orth, M. F., Dallmayer, M., Marchetto, A., Gerke, J. S., Rubío, R. A., Kıran, M. M., Musa, J., Knott, M. M. L., Ohmura, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20098 · Cited by 93
Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors
Richters, A., Doyle, S. K., Freeman, D. B., Lee, C., Leifer, B. S., Jagannathan, S., Kabinger, F., Koren, J. V., Struntz, N. B., Urgiles, J., et al. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.10.001 · Cited by 86
Self-citation
Large-Scale Identification of Coregulated Enhancer Networks in the Adult Human Brain
Vermunt, M. W., Reinink, P., Korving, J., de Bruijn, E., Creyghton, P. M., Başak, O., Geeven, G., Toonen, P. W., Lansu, N. R., Meunier, C., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.09.023 · Cited by 86
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
Bolin, S., Borgenvik, A., Persson, C., Sundström, A., Qi, J., Bradner, J. E., Weiss, W. A., Cho, Y., Weishaupt, H., & Swartling, F. J. (2018) · Oncogene · doi:10.1038/s41388-018-0135-1 · Cited by 88
Self-citation
Targets for protection and mitigation of radiation injury
Khodamoradi, E., Hoseini‐Ghahfarokhi, M., Amini, P., Motevaseli, E., Shabeeb, D., Musa, A. E., Najafi, M., & Farhood, B. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03479-x · Cited by 88
Aldehyde dehydrogenase 1A1 and 1A3 isoforms – mechanism of activation and regulation in cancer
Poturnajova, M., Kozovská, Z., & Matúšková, M. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110120 · Cited by 86
The roles of epigenetics in cancer progression and metastasis
Chen, J. F.-Y., & Yan, Q. (2021) · Biochemical Journal · doi:10.1042/bcj20210084 · Cited by 89
MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation
Sdelci, S., Rendeiro, A. F., Rathert, P., You, W., Lin, J.-M. G., Ringler, A., Hofstätter, G., Moll, H. P., Gürtl, B., Farlik, M., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0413-z · Cited by 85
Self-citation
Modeling cis-regulation with a compendium of genome-wide histone H3K27ac profilesPreprint
Wang, S., Zang, C., Xiao, T., Fan, J., Mei, S., Qin, Q., Wu, Q., Li, X., Xu, K., He, H. H., et al. (2016) · Genome Research · doi:10.1101/gr.201574.115 · Cited by 81
Chromatin architecture transitions from zebrafish sperm through early embryogenesisPreprint
Wike, C. L., Guo, Y., Tan, M., Nakamura, R., Shaw, D. K., Díaz, N., Whittaker-Tademy, A. F., Durand, N. C., Aiden, E. L., Vaquerizas, J. M., et al. (2021) · Genome Research · doi:10.1101/gr.269860.120 · Cited by 87
Transcriptional Pause Release Is a Rate-Limiting Step for Somatic Cell Reprogramming
Liu, L., Xu, Y., He, M., Zhang, M., Cui, F., Lu, L., Yao, M., Tian, W., Benda, C., Zhuang, Q., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.09.018 · Cited by 85
CBP/p300 acetyltransferase activity in hematologic malignancies
Dutta, R., Tiu, B. C., & Sakamoto, K. M. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.06.013 · Cited by 84
Tandemly Integrated HPV16 Can Form a Brd4-Dependent Super-Enhancer-Like Element That Drives Transcription of Viral Oncogenes
Dooley, K. E., Warburton, A., & McBride, A. A. (2016) · mBio · doi:10.1128/mbio.01446-16 · Cited by 86
MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia
Kerry, J., Godfrey, L., Repapi, E., Tapia, M. C., Blackledge, N. P., Ma, H., Ballabio, E., O’Byrne, S., Ponthan, F., Heidenreich, O. T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.054 · Cited by 79
Non-coding Transcripts from Enhancers: New Insights into Enhancer Activity and Gene Expression Regulation
Chen, H., Du, G., Song, X., & Li, L. (2017) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2017.02.003 · Cited by 85
Combined Cohesin–RUNX1 Deficiency Synergistically Perturbs Chromatin Looping and Causes Myelodysplastic Syndromes
Ochi, Y., Kon, A., Sakata, T., Nakagawa, M. M., Nakazawa, N., Kakuta, M., Kataoka, K., Koseki, H., Nakayama, M., Morishita, D., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0982 · Cited by 86
SMARCB1-Deficient Cancers: Novel Molecular Insights and Therapeutic Vulnerabilities
Cooper, G. W., & Hong, A. L. (2022) · Cancers · doi:10.3390/cancers14153645 · Cited by 85
Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma
Sengupta, D., Kannan, A., Kern, M., Moreno, M. A., Vural, E. A., Stack, B. C., Suen, J. Y., Tackett, A. J., & Gao, L. (2015) · Epigenetics · doi:10.1080/15592294.2015.1034416 · Cited by 87
Joint annotation of chromatin state and chromatin conformation reveals relationships among domain types and identifies domains of cell-type-specific expression
Libbrecht, M. W., Ay, F., Hoffman, M. M., Gilbert, D. M., Bilmes, J. A., & Noble, W. S. (2015) · Genome Research · doi:10.1101/gr.184341.114 · Cited by 84
Chromatin kinases act on transcription factors and histone tails in regulation of inducible transcription
Josefowicz, S. Z., Shimada, M., Armache, A., Li, C. H., Miller, R. M., Lin, S., Yang, A., Dill, B. D., Molina, H., Park, H.-S., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.09.026 · Cited by 84
Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
Manzotti, G., Ciarrocchi, A., & Sancisi, V. (2019) · Cancers · doi:10.3390/cancers11030304 · Cited by 84
BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models
Zhao, X., Ren, Y., Lawlor, M. A., Shah, B. D., Park, P. M. C., Lwin, T., Wang, X., Liu, K., Wang, M. Y., Gao, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.04.005 · Cited by 88
Dose-dependent activation of gene expression is achieved using CRISPR and small molecules that recruit endogenous chromatin machinery
Chiarella, A. M., Butler, K. V., Gryder, B. E., Lu, D., Wang, T. A., Yu, X., Pomella, S., Khan, J. I., Jin, J. J., & Hathaway, N. A. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0296-7 · Cited by 85

Authors: Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A.
Affiliations: Whitehead Institute for Biomedical Research (US)
Dana-Farber Cancer Institute (US)
Cold Spring Harbor Laboratory (US)
Harvard University (US)
Corresponding author: Young, Richard A.
ORCID: Lin, Charles Y.
Orlando, David A.
Vakoc, Christopher R.
Bradner, James E.
Lee, Tong Ihn
Young, Richard A.
Venue: Cell
Publisher: Elsevier BV
Published: 2013-04
Volume: 153
Issue: 2
Pages: 320-334
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2013.03.036
PMC: PMC3760967
OpenAlex: W1523117612
Cited by: 2,961
References: 86
Citations by year: 2026: 140 · 2025: 214 · 2024: 261 · 2023: 254 · 2022: 271 · 2021: 327 · 2020: 263 · 2019: 248 · 2018: 218 · 2017: 205 · 2016: 184 · 2015: 175 · 2014: 143 · 2013: 53
FWCI: 83.08
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 375 d)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
Funders: National Institutes of Health (5p30ca045508-35)
National Human Genome Research Institute (HG002668, R01HG002668)
National Cancer Institute (CA146445, R01CA146445, P30-CA045508, CA45508, P30CA014051)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords: super-enhancers, BRD4, MYC oncogene, multiple myeloma, BET inhibitors, JQ1, Mediator complex, transcriptional coactivator, transcription elongation, chromatin regulators, cancer therapy, enhancer disruption
MeSH terms: Bromodomain Containing Proteins, Antineoplastic Agents, Azepines, Chromatin, Enhancer Elements, Genetic, Humans, Multiple Myeloma, Neoplasms, Nuclear Proteins, Transcription Factors, Transcription, Genetic, Triazoles, Gene Expression Regulation, Neoplastic, Cell Cycle Proteins, Cell Line, Tumor, Genome-Wide Association Study, Mediator Complex, Transcription Elongation, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks